Joins OTCQX trading platform

RNS Number:9857Q
Phynova Group PLC
28 March 2008



Press Release                                                      28 March 2008



                               Phynova Group plc



                                  ("Phynova")



          Phynova to join the US International OTCQX trading platform

          Promises cost-effective access to US investor liquidity pool



Phynova Group plc (AIM: PYN), the developer of prescription pharmaceuticals
derived from plants used in Chinese medicines, today announces that in April it
will establish a sponsored level one American Depositary Receipt ("ADR")
programme on the US International OTCQX platform under the symbol PHNVY.
Phynova will issue ADRs in respect of up to 25% of its issued share capital and
each ADR will represent 10 ordinary Phynova shares.  Phynova is retaining its
primary listing on the UK AIM market.



The International OTCQX is a new electronic platform for non-US companies that
are already listed on certain qualifying international exchanges, including the
UK's AIM market.  In an interview last year R. Cromwell Coulson, Chairman and
CEO of Pink Sheets, LLC, which operates International OTCQX, said: "It's
imperative to create a listing process that's cost-efficient for smaller
companies.  We looked at the London Stock Exchange's successful AIM market and
decided to offer a US answer".  AIM and other similar markets have deliberately
adopted a simplified regulatory climate in order to attract smaller fast-growing
companies.  So long as an OTCQX-traded company complies with the regulatory
environment of its primary exchange, it is relieved of the obligation to undergo
Securities and Exchange Commission ("SEC") registration and reporting.  Many
commentators have pointed out that compliance with SEC regulations, including
adopting US GAAP accounting and fulfilling the requirements of the
Sarbanes-Oxley Act, is a burden that makes trading in the US prohibitively
expensive for many international companies, especially smaller businesses.



Robert Miller, Phynova's CEO, said: "We see OTCQX as a unique and valuable
opportunity.  We will be one of the first AIM-listed stocks to have our ADRs
traded on this new platform.  We believe OTCQX will provide cost-effective
access to US investors, who have shown a growing appetite for investing in
non-US securities.  As of 30 September 2007, US investments in foreign equities
amounted to $4.9 trillion, 22% of all US equity investments, against less than
9% a decade ago.  We expect Phynova's focus on the fast-growing Chinese
pharmaceutical market to be of particular interest to US investors and we are
optimistic that US interest will translate into improved liquidity in our
shares."



Phynova has appointed The Bank of New York Mellon to serve as Principal American
Liaison ("PAL") for its OTCQX quotation.  The Bank of New York Mellon will be
responsible for maintaining Phynova's Level one ADR programme as well as
advising on disclosure requirements and communications with the US market.  The
Bank of New York Mellon, the leading global depositary for Depositary Receipts,
will also act as depositary for Phynova's ADRs.

                                    - Ends -

For further information, please contact:


Phynova Group PLC                                            +44 (0) 1993 880700
Robert Miller, Chief Executive Officer                           www.phynova.com

Nominated Adviser:
Nabarro Wells & Co. Limited                                 +44 (0) 20 7710 7400
Marc Cramsie

Broker:
Evolution Securities China Limited                          +44 (0) 20 7220 4850
Barry Saint


The Bank of New York Mellon                                    +1 (212) 815 2077
Jason Paltrowitz



Media enquiries:
Abchurch Communications                                     +44 (0) 20 7398 7700
Peter Laing/Ashley Tapp/Stephanie Cuthbert
ashley.tapp@abchurch-group.com                            www.abchurch-group.com



Notes to Editors:



About Phynova

Phynova is a UK company developing prescription pharmaceuticals derived from
plants used in Chinese medicines. Phynova is focused on viral and metabolic
diseases and cancer. Phynova's lead product for hepatitis C has now completed a
Phase I/II trial in the US and the Phase IIb trial is scheduled to commence in
the first half of 2008. Two further products, for fatty liver disease and
post-operative ileus, are targeted for entry to the clinic over the next six
months and there are a further four products in preclinical development. For
further information please visit www.phynova.com.



About International OTCQX

Launched in March 2007 and operated by Pink Sheets, LLC, the International OTCQX
provides a gateway to U.S. securities markets for international companies that
are listed on a qualified international exchange and which undertake to provide
ongoing disclosure (in English) to U.S. investors. The OTCQX distinguishes the
reputable international issuers from the 8,000 over-the-counter (OTC) securities
traded in the U.S. Only leading companies that have substantial operating
businesses and provide credible disclosure to the public are eligible for
inclusion on the premium-tier International OTCQX. Each company listed on
International OTCQX must appoint a Principal American Liaison (PAL) to act as
sponsor and to ensure compliance with disclosure regulations. Major non-US
companies whose shares are now traded on the OTCQX platform (sometimes delisting
from other US exchanges) include British Gas, Nestle, Roche, Tate & Lyle, BASF
and Akzo Nobel. For more about International OTCQX, visit www.otcqx.com.



About Pink Sheets, LLC

Pink Sheets, LLC is the leading electronic inter-dealer quotation system,
trading technology and financial information provider for the over-the-counter
(OTC) securities markets. Its centralized information network includes services
designed to benefit market makers, issuers, brokers and OTC investors. Pink
Sheets information enhances the efficiency of OTC trading, provides better
executions for OTC investors and improves the capital formation process for OTC
issuers. For more information visit the Pink Sheets website at
www.pinksheets.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

MSCVDLFLVXBEBBX
Phynova (LSE:PYN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024